Core Viewpoint - Novartis plans to build a radioligand therapy manufacturing site in Texas, marking its first facility of this kind in the state and the fifth in the U.S. [1][4] Group 1: Investment and Expansion - The investment is part of Novartis' broader strategy to spend $23 billion on building and expanding facilities in the U.S. [2] - The new Texas site will enhance Novartis' manufacturing capacity in response to increased domestic demand and regulatory pressures [2][3]. Group 2: Facility Details - The new facility will cover 46,000 square feet and is expected to be fully operational by 2028 [4]. - The site will create jobs in bioengineering, advanced manufacturing, quality, and operations [4]. Group 3: Product Focus - Radioligand therapy is a targeted cancer treatment that delivers radiation directly to tumor cells, with Novartis already marketing Pluvicto and Lutathera for specific cancers [4]. - The addition of this facility will strengthen Novartis' ability to meet the growing demand for next-generation cancer treatments [3].

Core Insights - Plus Therapeutics has received approval for a new Category III CPT code from the American Medical Association to track the utilization of convection-enhanced delivery (CED) for REYOBIQ therapy in recurrent glioblastoma and pediatric brain cancer, marking a significant step towards market access and commercialization [1][2] Group 1: REYOBIQ Therapy - REYOBIQ (rhenium Re186 obisbemeda) is a novel injectable radiotherapy designed to deliver targeted high-dose radiation to CNS tumors, potentially improving patient outcomes compared to existing therapies [3] - The therapy is currently being evaluated in clinical trials for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer, with significant funding support from various institutions, including a $17.6 million grant from the Cancer Prevention & Research Institute of Texas [3] Group 2: Market Access and Utilization Tracking - The approved Category III CPT code, X566T, will facilitate the tracking of CED procedures for REYOBIQ, aiding in the evaluation of its clinical use and supporting future reimbursement and coverage decisions [2] - The new CPT code will be published on July 1, 2026, and will take effect for reporting on January 1, 2027, which is expected to enhance the adoption of REYOBIQ in clinical settings [2] Group 3: Company Overview - Plus Therapeutics is a clinical-stage pharmaceutical company based in Houston, Texas, focused on developing targeted radiotherapeutics for challenging CNS cancers, aiming to improve clinical outcomes through innovative treatment approaches [4] - The company has established a supply chain through strategic partnerships to support the development, manufacturing, and potential commercialization of its products [4]

are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, the FDA's ability to complete its review of, and reach a decision with respect to, the imsidolimab BLA by December 12, 2026; Vanda's assumptions regarding how imsidolimab achieves its therapeutic effect; Vanda's ability to obtain FDA approval ...

千亿注射剂市场风云再起！2025年前三季度，全终端医院注射剂销售额虽同比微降，但生物药强势崛起、独家品种爆发式增长，TOP50榜单迎来大洗牌。13 款新品跻身榜单，1款独家注射剂同比劲增92.26%，齐鲁制药领衔本土药企，与外资分庭抗礼。 4500亿注射剂市场，生物药占居主导 据摩熵医药数据库(https://vip.pharnexcloud.com/?zmt-mhwz)显示，2025年Q1-Q3全终端医院市场（化药+生物药+中成药）中，注射剂销售额突破 4500亿元， 同比下滑 9.76%。品类结构中，生物药 图源：摩熵医药-全终端医院销售数据库 回顾近年走势：2018-2023年注射剂销售额在6691.73亿~7557.34亿元间波动，2020年因多重因素探底至6691.73亿元，2023年回升至7043.94亿元；2024年受宏 观与政策影响回落至6482亿元，降幅约7.98%。进入2025年，前三季度同比再降9.76%，显示行业进入阶段性调整。 治疗领域三强：血液和造血系统药物（22.75%）、抗肿瘤及免疫调节药（22.27%）、系统用抗感染药（14.6%）稳居前三，合计占据近六成份额。 图源：摩熵医 ...

WARREN, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in four upcoming investor conferences in March as follows: TD Cowen 46th Annual Health Care Conference: Management will be available for 1x1 meetings on Tuesday, March 3rdLeerink Pa ...

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2025 and provided financial expectations for 2026. To view the detailed fourth quarter and full year 2025 earnings press release and presentation please visit the company's investor relations website at https://investor.alkermes.com. Alkermes will host a conference call and webcast presentation at 8:00 a.m. EST (1:00 p.m. GMT) today, to discuss these financial results an. ...

Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in USSite to serve patients in Southern US and add network capacity as RLT expands into earlier treatment lines and additional tumor typesCompany broke ground on 4 new manufacturing and R&D facilities, initiated 3 facility expansions, and announced 2 additional sites in last 10 months, rapidly making progress on its commitment to expand its US operations Basel, February 25, 2026 – Novartis, a l ...

Connecting Innovation to Purpose Corporate Presentation February 25, 2026 www.corbuspharma.com @corbuspharma NASDAQ: CRBP 1 Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's trial results, product development, clinical and regulatory timelines, market op ...

BERKELEY HEIGHTS, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today announced that the management team will participate in two upcoming investor conferences in March 2026: TD Cowen 46th Annual Healthcare ConferenceCompany PresentationPresenter: Seth Lederman, M.D., President and Chief Executive Officer of Tonix PharmaceuticalsDate: Wednesday March 4, 2026Place: Boston Marriott Cop ...

Strategic Initiatives and Refined Business Model Produced Financial and Operating Efficiencies Established Long-Term License and Supply Agreement to Commercialize VAZKEPA® Across Europe and Sustained U.S. Market Leadership for VASCEPA® Franchise Total of 45 Publications (Abstracts, Posters, Manuscripts) Furthering the Expansion of the VASCEPA® /VAZKEPA® (icosapent ethyl) Body of Knowledge Supported in 2025 DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDA ...